Shan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shan Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sridhar Hannenhalli
Cancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, 20814
3 shared publications - Arashdeep Singh
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2 shared publications - David Y. Takeda
National Cancer Institute
2 shared publications - Dimple Notani
National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bengaluru, 560065, India
2 shared publications - Kaniz Fatema
Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
2 shared publications - Ivan Ovcharenko
Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10202
Non-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Prostate cancer (PrCa) incidence and severity vary across ancestries; men of African ancestry (AA) are more likely to be diagnosed and die from PrCa than those of European ancestry (EA). Current polygenic risk scores, even from multi-ancestry GWAS, do not fully capture population-specific genetic mechanisms, especially those mediated by non-coding regulatory single nucleotide polymorphisms (SNPs). Using a deep learning model of prostate enhancers, we identify ~ 2000 SNPs, potentially affecting enhancer function, with higher alternate allele frequency in AA men, that may affect PrCa risk. These SNPs may promote cancer via two mechanisms: increased enhancer activity leading to immune suppression and telomere elongation or decreased activity causing de-differentiation and apoptosis inhibition. Identified SNPs predominantly modulate binding of key transcription factors such as FOX, HOX, and AR – the first was experimentally validated. Incorporating these SNPs into a polygenic risk score improves PrCa risk assessment beyond existing GWAS-identified variants.
- 20 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10202
Open AccessNon-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Prostate cancer (PrCa) incidence and severity vary across ancestries; men of African ancestry (AA) are more likely to be diagnosed and die from PrCa than those of European ancestry (EA). Current polygenic risk scores, even from multi-ancestry GWAS, do not fully capture population-specific genetic mechanisms, especially those mediated by non-coding regulatory single nucleotide polymorphisms (SNPs). Using a deep learning model of prostate enhancers, we identify ~ 2000 SNPs, potentially affecting enhancer function, with higher alternate allele frequency in AA men, that may affect PrCa risk. These SNPs may promote cancer via two mechanisms: increased enhancer activity leading to immune suppression and telomere elongation or decreased activity causing de-differentiation and apoptosis inhibition. Identified SNPs predominantly modulate binding of key transcription factors such as FOX, HOX, and AR – the first was experimentally validated. Incorporating these SNPs into a polygenic risk score improves PrCa risk assessment beyond existing GWAS-identified variants.
- Open Access
- 5 December 2024
- Published by Springer Nature in Research Square
Non-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Incidence and severity of prostate cancer (PrCa) substantially varies across ancestries. American men of African ancestry (AA) are more likely to be diagnosed with and die from PrCa than the those of European ancestry (EA). Published polygenic risk scores for developing prostate cancer, even those based on multi-ancestry genome-wide association studies, do not address population-specific genetic mechanisms underlying PrCa risk in men of African ancestry. Specifically, the role of non-coding regulatory polymorphisms in driving inter-ancestry variation in PrCa has not been sufficiently explored. Here, by employing a sequence-based deep learning model of prostate regulatory enhancers, we identified ~ 2,000 SNPs with higher alternate allele frequency in AA men that potentially affect enhancer function associated with PrCa susceptibility, as supported by our experimental validation. The identified enhancer SNPs (eSNPs) may influence PrCa development through two complementary mechanisms: 1) the alternate allele that increase enhancer activity result in immune suppression and telomere elongation, and 2) the alternate alleles that decrease enhancer activity, lead to de-differentiation and inhibition of apoptosis. Notably, the eSNPs tend to disrupt the binding of known prostate transcription factors including FOX, AR and HOX families. Lastly, the identified eSNPs can be combined into a polygenic risk score that adds value to current GWAS-based risk variants in assessing PrCa risk in independent cohorts.
- 5 December 2024
- Published by Springer Nature in Research Square
Open AccessNon-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Incidence and severity of prostate cancer (PrCa) substantially varies across ancestries. American men of African ancestry (AA) are more likely to be diagnosed with and die from PrCa than the those of European ancestry (EA). Published polygenic risk scores for developing prostate cancer, even those based on multi-ancestry genome-wide association studies, do not address population-specific genetic mechanisms underlying PrCa risk in men of African ancestry. Specifically, the role of non-coding regulatory polymorphisms in driving inter-ancestry variation in PrCa has not been sufficiently explored. Here, by employing a sequence-based deep learning model of prostate regulatory enhancers, we identified ~ 2,000 SNPs with higher alternate allele frequency in AA men that potentially affect enhancer function associated with PrCa susceptibility, as supported by our experimental validation. The identified enhancer SNPs (eSNPs) may influence PrCa development through two complementary mechanisms: 1) the alternate allele that increase enhancer activity result in immune suppression and telomere elongation, and 2) the alternate alleles that decrease enhancer activity, lead to de-differentiation and inhibition of apoptosis. Notably, the eSNPs tend to disrupt the binding of known prostate transcription factors including FOX, AR and HOX families. Lastly, the identified eSNPs can be combined into a polygenic risk score that adds value to current GWAS-based risk variants in assessing PrCa risk in independent cohorts.
- 17 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (7) , eadd2911
De novo human brain enhancers created by single-nucleotide mutations
Advanced human cognition is attributed to increased neocortex size and complexity, but the underlying evolutionary and regulatory mechanisms are largely unknown. Using human and macaque embryonic neocortical H3K27ac data coupled with a deep learning model of enhancers, we identified ~4000 enhancer gains in humans, which, per our model, can often be attributed to single-nucleotide essential mutations. Our analyses suggest that functional gains in embryonic brain development are associated with de novo enhancers whose putative target genes exhibit increased expression in progenitor cells and interneurons and partake in critical neural developmental processes. Essential mutations alter enhancer activity through altered binding of key transcription factors (TFs) of embryonic neocortex, including ISL1, POU3F2, PITX1/2, and several SOX TFs, and are associated with central nervous system disorders. Overall, our results suggest that essential mutations lead to gain of embryonic neocortex enhancers, which orchestrate expression of genes involved in critical developmental processes associated with human cognition.
- 17 February 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (7) , eadd2911
De novo human brain enhancers created by single-nucleotide mutations
Advanced human cognition is attributed to increased neocortex size and complexity, but the underlying evolutionary and regulatory mechanisms are largely unknown. Using human and macaque embryonic neocortical H3K27ac data coupled with a deep learning model of enhancers, we identified ~4000 enhancer gains in humans, which, per our model, can often be attributed to single-nucleotide essential mutations. Our analyses suggest that functional gains in embryonic brain development are associated with de novo enhancers whose putative target genes exhibit increased expression in progenitor cells and interneurons and partake in critical neural developmental processes. Essential mutations alter enhancer activity through altered binding of key transcription factors (TFs) of embryonic neocortex, including ISL1, POU3F2, PITX1/2, and several SOX TFs, and are associated with central nervous system disorders. Overall, our results suggest that essential mutations lead to gain of embryonic neocortex enhancers, which orchestrate expression of genes involved in critical developmental processes associated with human cognition.